04.12.2020 14:12:12

Lilly, UnitedHealth Partner On Pragmatic Study Of Bamlanivimab For COVID-19

(RTTNews) - Eli Lilly and Company (LLY) and UnitedHealth Group (UNH) has partnered to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. The study will evaluate the efficacy and safety of bamlanivimab versus a propensity-matched control in individuals that meet the EUA criteria.

Bamlanivimab recently received Emergency Use Authorization for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

The study is part of a collaborative partnership between OptumLabs, the scientific research arm of UnitedHealth Group, and Lilly.

Analysen zu UnitedHealth Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Eli Lilly 747,70 -0,41% Eli Lilly
UnitedHealth Inc. 487,10 -1,04% UnitedHealth Inc.